Search tips
Search criteria 


Logo of adnaLink to Publisher's site
Artif DNA PNA XNA. 2014 Sep-Dec; 5(3): e1146391.
Published online 2016 February 11. doi:  10.1080/1949095X.2016.1146391
PMCID: PMC5329896

Effect of 2′-O-methyl/thiophosphonoacetate-modified antisense oligonucleotides on huntingtin expression in patient-derived cells


Optimizing oligonucleotides as therapeutics will require exploring how chemistry can be used to enhance their effects inside cells. To achieve this goal it will be necessary to fully explore chemical space around the native DNA/RNA framework to define the potential of diverse chemical modifications. In this report we examine the potential of thiophosphonoacetate (thioPACE)-modified 2′-O-methyl oligoribonucleotides as inhibitors of human huntingtin (HTT) expression. Inhibition occurred, but was less than with analogous locked nucleic acid (LNA)-substituted oligomers lacking the thioPACE modification. These data suggest that thioPACE oligonucleotides have the potential to control gene expression inside cells. However, advantages relative to other modifications were not demonstrated. Additional modifications are likely to be necessary to fully explore any potential advantages of thioPACE substitutions.

Keywords: antisense oligonucleotides, huntingtin, Huntington's disease, locked nucleic acids, phosphate modification, thiophosphonoacetate


locked nucleic acid
Huntington's disease.


The development of nucleic acid therapeutics is challenging because of the need to optimize efficacy, potency, pharmacokinetics, and cellular delivery while minimizing potentially toxic off-target effects.1 The difficulty of overcoming these challenges explains why only three oligonucleotide-based drugs have been approved after approximately 25 years of commercial development. Progress will require fully exploring the potential of chemical modifications to improve their properties.

Thiophosphonoacetate (thioPACE)-modified oligonucleotides contain an acetate group in place of a non-bridging oxygen within the phosphate linkage, as well as a phosphorothioate substitution.2-4 These modifications are a substantial departure from normal phosphodiester linkages and have the potential to significantly alter hybridization and cell uptake. Previous work has shown that thioPACE oligonucleotides can activate RNase H1 in vitro,2,3 are stable to nuclease digestion,2,3 are more easily taken up into cells,4 and improve the inhibition of microRNA-122 in Huh7 cells compared with phosphonoacetate (PACE) or 2′-OMe phosphorothioate oligonucleotides.4 Recently, thioPACE modified CRISPR RNA has been shown to stabilize the CRISPR-Cas system when transfected into primary cells.5

Huntington's disease (HD)6 is a currently incurable genetic disease caused by an expansion of the trinucleotide CAG within the huntingtin (HTT) gene. Other diseases caused by CAG expansions include dentatorubral-pallidoluysian atrophy (DRPLA,7 within the atrophin-1 gene) and Machado-Joseph disease8 (within the gene encoding ataxin-3). Because expanded CAG repeats are the cause of these diseases, an agent complementary to CAG repeats would have the potential to treat multiple neurological conditions.

We have previously shown that synthetic nucleic acids complementary to CAG repeats can inhibit the expression of mutant proteins including Htt,9-13,15 ataxin-3,9,14-16 and atrophin-1.17 Inhibition is allele selective, with anti-CAG oligomers demonstrating up to 40-fold selectivity for blocking expression of mutant protein versus wild-type.11 Oligomers that were capable of allele-selective inhibition included peptide nucleic acids,9 locked nucleic acids,9,10 carba-locked nucleic acids,10 2′,4′-constrained ethylene-bridged nucleic acids,10 single-stranded silencing RNA,12,13,15-17 mismatch-containing duplex RNA,11,17 abasic-substituted duplex RNA,14 and unlocked nucleic acids.16

These studies have shown that expanded CAG repeats are an excellent model for evaluating the potential of chemically modified nucleic acids for the recognition of challenging cellular RNA targets. In this study we test the potential of thioPACE oligonucleotides for recognition of the expanded repeat within mutant HTT mRNA.


Oligonucleotides were transfected into patient-derived GM04281 fibroblast cells. GM04281 cells contain a wild-type HTT allele with 17 CAG repeats and a mutant allele with 69 CAG repeats. Oligonucleotides were also introduced into mouse striatal neuron-derived cells STHdhQ7/Q111 with seven wild-type repeats and 111 mutant repeats. Oligonucleotides were introduced into cells by using cationic lipids and inhibition of HTT protein (Htt) expression was evaluated by western blot analysis. Experiments were performed in triplicate.

A locked nucleic acid (LNA) oligonucleotide (LNA(T)-PS) that had previously been shown to be a potent and allele selective inhibitor of HTT protein expression was used as a positive control (Fig. 1A).10 A noncomplementary LNA was used as a negative control. Compounds 1 and 3 had four 2′-O-methyl/thiophosphonoacetate substitutions (Fig. 1A and B). Compounds 2 and 3 were based on the positive control LNA and had six LNA substitutions.

Figure 1.
CAG-repeat-targeting antisense oligonucleotides (ASOs) used in this study. (A) Sequences and chemical modification of CAG-repeat targeting antisense oligonucleotides for HTT inhibition. (B) Structure of 2′-O-methyl thiophosphonoacetate oligonucleotide. ...

LNA substitutions increase the melting temperature (Tm) values of oligonucleotides that contain them. The Tm values for the oligonucleotides used in this study were determined by differential scanning calorimetry. These measures revealed that the Tm values for complementary RNA and the positive control LNA or 2′-O-methyl/thioPACE oligonucleotide 1 were both approximately 94°C (Fig. 1AC). The Tm value of 109.2°C for oligonucleotide 2 was significantly higher than the 94.2°C recorded for LNA(T)-PS. Because both oligonucleotides contain six LNA substitutions, these data confirm that multiple 2′-O-methyl modification increases binding affinity in this system, as it is known to in others.18 Previous research showed that thiophosphonoacetate modification decreases Tm by 0.75°C per modification.4 Consistent with this, the Tm for oligonucleotide 3, which contained four thiophosphonoaceate substitutions, was 105.5°C, which was lower relative to 109.2°C for oligonucleotide 2.

Analysis of GM04281 cells transfected with 100 nM oligonucleotide revealed significant inhibition of HTT expression by the positive control LNA (T)-PS and by oligonucleotides 2 and 3 relative to the noncomplementary negative control oligonucleotides or untreated control cells (Fig. 2A). While the LNA (T)-PS significantly and allele-selectively inhibited HTT expression, oligonucleotides 2 and 3 did not achieve allele-selective inhibition. We also examined inhibition in STHdhQ7/111 cells (Fig. 2B). LNA (T)-PS again potently and allele-selectively inhibited HTT expression, as did oligonucleotide 1. Oligonucleotides 2 and 3, possessing higher Tm values for complementary RNA, were less potent for inhibiting mutant or wild-type Htt protein expression.

Figure 2.
Inhibition of HTT expression by chemically modified single-stranded antisense oligonucleotides targeting CAG repeats of HTT mRNA. Top: western blot analysis: bottom: quantification of triplicate independent experiments. Oligonucleotides were transfected ...

To gain insights into the potency of LNA and thioPACE oligonucleotides we transfected the compounds into GM04281 cells at a range of concentrations (0, 6.25, 12.5, 25, 50, and 100 nM). The negative control oligonucleotide did not inhibit HTT protein expression at any concentration (Fig. 3A) while the inhibition with the positive control LNA was potent and allele selective (IC50(mut)=44 ± 7 nM, IC50(wt)>100 nM) (Fig. 3B). Inhibition of HTT expression after addition of the two thioPACE oligonucleotides 1 and 3 and control oligonucleotide 2 was less allele-selective (IC50(mut)=47 ± 9 nM (Oligo2) and ~100 nM (Oligo1,3); IC50(wt)>100 nM(Oligo1,2,3)) (Fig. 3C-E) than positive control LNA(T)-PS.

Figure 3.
Dose-response profiles of CAG-repeat-targeting single-stranded antisense oligonucleotides (LNA(T)-PS (B), Oligo1 (C), Oligo2 (D), Oligo3 (E)), and negative control (−Ctrl (A)) for HTT inhibition. Each oligomer was transfected into GM04281 fibroblast ...


Our experiments provide significant insights into the potential of thioPACE oligonucleotides to recognize a challenging RNA target. We find that thioPACE oligonucleotides can enter cells when delivered with cationic lipid and block expression of HTT. Potent and allele-selective inhibition was achieved in striatal-derived cell line STHdhQ7/Q111, possibly aided by the large number of CAG repeats within the mutant allele. Allele-selective inhibition was much less apparent in GM04281 cells.

While our experiments demonstrate that thioPACE oligonucleotides can achieve inhibition of HTT protein expression, it is also clear that further refinement is necessary to explore the full potential of the modification. Although oligonucleotide 1, which contained four 2′-O-methyl/thioPACE modifications, retained a similar Tm value relative to the positive control LNA(T)-PS, inhibition of mutant HTT by oligonucleotide 1 was not as strong and allele selectivity was reduced, suggesting that chemical structure is a key factor in determining potency and selectivity for HTT inhibition.

It also appears that overall thermodynamic stability of repeat-targeting antisense oligonucleotides to complementary targets is important. Indeed, inhibition and selectivity was better with LNA(T)-PS and oligonucleotide 1, which had lower Tm values, in STHdhQ7/Q111 cells compared with oligonucleotides 2 and 3, which had higher Tm values. These results suggest that a higher Tm of oligonucleotides may contribute to the lack of allele-selective inhibition in STHdhQ7/Q111 and GM04281 cells by overpowering the subtle differences in recognition between the mutant and wild-type alleles.

The compounds tested in these studies contained only four thioPACE substitutions. It will be interesting in the future to examine compounds with more extensive thioPACE modification in different modification patterns. Additional thioPACE substitutions might affect cellular uptake, lysosomal release, or cytoplasmic localization. The possession of better developed structure activity relationships through testing additional compounds might also lead to identification of optimized compounds with superior properties.

Materials and Methods

Measurement of melting temperature by differential scanning calorimetry

Melting temperatures (Tm) for antisense oligonuceotide:RNA (CAGCAGCAGCAGCAGCAGC) duplexes were measured on a MicroCal VP-DSC capillary cell microcalorimeter (Malvern Instruments). Duplexes (10 μM) in phosphate buffer (10 mM Na2HPO4/NaH2PO4, 150 mM NaCl, and 1 mM ethylenediaminetetraacetic acid (EDTA); pH 7.2) were annealed by heating to 95°C and then gradually cooling to room temperature. Samples were scanned under pressure from 40–130°C at a scan rate of 90°C/h with two rescans. The temperature corresponding to the maximum peak in heat capacity (Cp) was taken as the Tm.

Cell culture and transfection

HD patient-derived fibroblast cells GM04281 (Coriell) were cultured at 37°C and 5% CO2 in Minimum Essential Medium Eagle (Sigma) supplemented with 0.5% MEM nonessential amino acids (Sigma) and 10% fetal bovine serum (FBS). Mouse striatal neuron-derived cells STHdhQ7/Q111 (Coriell) were cultured at 37°C and 5% CO2 in Dulbecco's Modified Eagle's Medium (Sigma) supplemented with 10% FBS. Cells were seeded in six-well plates at 60,000 cells/well two days before transfection. Cells were transfected with oligonucleotides by using Lipofectamine RNAiMAX (Invitrogen). Cells were harvested for protein gel blot analysis four days after transfection.

Western blot analysis

Cells were lysed using lysis buffer (50 mM Tris-HCl, 120 mM NaCl, 0.5% NP-40, 1 mM EDTA, 1 mM dithiothreitol (DTT), and protease inhibitor (Calbiochem). Protein concentrations were determined by using a BCA assay kit (Themo Scientific). SDS-PAGE was performed using 5% Tris-acetate gel (2.8% crosslinker) for Htt or 7.5% Tris-HCl gel (3.8% crosslinker, Bio-Rad) for β-actin. Gels were run at 100 V for 5 h (Htt) or 1 h (β-actin). After gel electrophoresis, proteins were transferred to a nitrocellulose membrane (Hybond C-Extra, GE Healthcare). Membranes were blocked using 5% non-fat dry milk/PBST and then incubated with primary antibodies specific for Htt (MAB2166, 1:10,000, EMD Millipore) or β-actin (A5441, 1:20,000, Sigma). Horseradish peroxidase (HRP)-conjugated anti-mouse IgG secondary antibody (715–035–150, Jackson ImmunoResearch) was used for visualizing proteins by using Supersignal West Pico Chemiluminescent Substrate (Thermo Scientific). Protein bands were quantified by using Image J software. Data plots from dose response experiments were fitted to the following equation: y = 100(1-xm/(nm+xm)), where y is percent expression of HTT and x is concentration of synthetic oligomers. m and n are fitting parameters, where n is taken as the IC50 value (± SE from the fit).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.


This work was supported by the US National Institutes of Health (NIGMS 73042), and the Robert A. Welch Foundation (I-1244) to D.R.C. D.R.C. holds the Rusty Kelley Professorship in Medical Science.


1. Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 2012; 19:937-54; PMID:22921062; [PubMed] [Cross Ref]
2. Dellinger DJ, Sheehan DM, Christensen NK, Lindberg JG, Caruthers MH. Solid-phase chemical synthesis of phosphonoacetate and thiophosphonoacetate oligodeoxynucleotides. J Am Chem Soc 2003; 125:940-50; PMID:12537492; [PubMed] [Cross Ref]
3. Sheehan D, Lunstad B, Yamada CM, Stell BG, Caruthers MH, Dellinger DJ. Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Nucleic Acids Res 2003; 31:4109-18; PMID:12853628; [PMC free article] [PubMed] [Cross Ref]
4. Threlfall RN, Torres AG, Krivenko A, Gait MJ, Caruthers MH. Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2′-O-methyl oligoribonucleotides. Org Biomol Chem 2012; 10:746-54; PMID:22124653; [PubMed] [Cross Ref]
5. Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 2015; 33:985-9; PMID:26121415; [PMC free article] [PubMed] [Cross Ref]
6. Walker FO.. Huntington's disease. Lancet 2007; 369:218-28; PMID:17240289; [PubMed] [Cross Ref]
7. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994; 6:9-13; PMID:8136840; [PubMed] [Cross Ref]
8. Paulson HL.. Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3. Semin Neurol 2007; 27:133-42; PMID:17390258; [PubMed] [Cross Ref]
9. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, Arar K, Wu J, Bezprozvanny I, Corey DR. (2009). Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009; 27:478-84; PMID:19412185; [PMC free article] [PubMed] [Cross Ref]
10. Gagnon KT, Pendergraff HM, Deleavey GF, Swayze EE, Potier P, Randolph J, Roesch EB, Chattopadhyaya J, Damha MJ, Bennett CF, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochem 2010; 49:10166-78; [PMC free article] [PubMed] [Cross Ref]
11. Hu J, Liu J, Corey DR. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 2010; 17:1183-8; PMID:21095568; [PMC free article] [PubMed] [Cross Ref]
12. Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE, Lima WF, Crooke ST, Prakash TP, Corey DR. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012; 150:895-908; PMID:22939619; [PMC free article] [PubMed] [Cross Ref]
13. Hu J, Liu J, Yu D, Aiba Y, Lee S, Pendergraff H, Boubaker J, Artates JW, Lagier-Tourenne C, Lima WF, et al. Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs. Nucleic Acid Ther 2014; 24:199-209; PMID:24694346; [PMC free article] [PubMed] [Cross Ref]
14. Liu J, Pendergraff H, Narayanannair KJ, Lackey JG, Kuchimanchi S, Rajeev KG, Manoharan M, Hu J, Corey DR. RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression. Nucleic Acids Res 2013; 41:8788-801; PMID:23887934; [PMC free article] [PubMed] [Cross Ref]
15. Liu J, Yu D, Aiba Y, Pendergraff H, Swayze EE, Lima WF, Hu J, Prakash TP, Corey DR. ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. Nucleic Acids Res 2013; 41:9570-83; PMID:23935115; [PMC free article] [PubMed] [Cross Ref]
16. Aiba Y, Hu J, Liu J, Xiang Q, Martinez C, Corey DR Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions. Biochem 2013; 52:9329-38; [PMC free article] [PubMed] [Cross Ref]
17. Hu J, Liu J, Narayanannair KJ, Lackey JG, Kuchimanchi S, Rajeev KG, Manoharan M, Swayze EE, Lima WF, Prakash TP, et al. Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochem 2014; 53:4510-8; [PMC free article] [PubMed] [Cross Ref]
18. Inoue H, Hayase Y, Imura A, Iwai S, Miura K, Ohtsuka E. Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res 1987; 15:6131-48; PMID:3627981; [PMC free article] [PubMed] [Cross Ref]

Articles from Artificial DNA, PNA & XNA are provided here courtesy of Taylor & Francis